Abstract:Objective To explore the effect of intermittent dosage regimen of rosuvastatin combined with ezetimibe on coronary atherosclerotic heart disease(CHD).Methods A total of 85 CHD patients who had statins intolerance from January 2016 to September 2016 in Beijing Anzhen Hospital,Capital Medical University were randomly divided into ezetimibe group(10 mg/d,n =43) and combined treatment group(ezetimibe 10 mg/d and rosuvastatin twice a week,n =42).Blood lipid indexes [total cholesterol(TC),triacylglycerol (TG),high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C)] before treatment and after 12 weeks of treatment were tested and adverse drug effects were recorded.Results Baseline data and reasons for statins intolerance had no significant differences between groups (P ＞ 0.05).TC and LDL-C significantly decreased after treatment compared to the baseline in both groups [ezetimibe group:(4.3 ± 0.8) mmol/L vs (5.2±0.9)mmol/L,(3.2 ±0.6)mmol/L vs (3.9 ±0.8)mmol/L;combined treatment group:(3.8 ±0.6)mmol/Lvs (5.2±0.8)mmol/L,(2.8±0.5)mmol/L vs (3.9 ±0.8)mmol/L](P＜0.05);TG and HDL-C had no significant difference before and after treatment in ezetimibe group;TG in combined treatment group significantly decreased after treatment and HDL-C significantly increased compared to the baseline [(1.4 ±0.4) mmol/L vs (2.2 ± 0.6) mmol/L,(1.6 ± 0.4) mmol/L vs (1.2 ± 0.3) mmol/L] (P ＜ 0.05).TC,TG and LDL-C in combined treatment group were significantly lower than those in ezetimibe group after treatment (P ＜ 0.05).The standard-reaching rate of LDL-C in ezetimibe group was 0;the standard-reaching rate of LDL-C in combined treatment group was 23.8％ (10/42);there was a significant difference between groups (P ＜0.05).No severe adverse reaction was observed during treatment.Conclusion Intermittent dosage regimen of rosuvastatin combined with ezetimibe treating CHD with statins intolerance can improve statins compliance and lipid-lowering effect.

Analysis of treatment effect of β-blockers combined with statins on chronic heart failure

Effects of Pravastatin on Cardiac Function and Plasma Level of Brain Natriuretic Peptide in Patients with Chronic Heart Failure

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials.

The observation of clinical curative effect of Irbesartan combined with Metoprolol on the congestive heart failure

Clinical Research of the Effect of Statin on Non-Ischemic Heart Failure

Effect of Simvastatin on the Improvement of Cardiac Function and CRP Level of Patients with Chronic Heart Failure

Observation on Effect of Combined Treatment of Traditional Chinese medicine and Western Medicine in Chronic Heart Failure

Observation of the Therapeutic Effect in Treating Chronic Heart Failure with High-Sensible Β-Blocker

Effect Analysis of Metoprolol With Benazepril for Treatment of Senile Chronic Heart Failure

Efficacy of β-blocker in the treatment of 90 senile patients with chronic heart failure

Effects of Bisoprolol and Metoprolol in 223 Patients with Chronic Congestive Heart Failure

Efficacy of intermittent dosage regimen of rosuvastatin combined with ezetimibe in treatment of coronary atherosclerotic heart disease

Effict of Calcium Channel Blocker in the Treatment of Hypertension Patients with Mild Heart Failure

E0368 Evaluation of the Effect on the Management of Patients Suffering from Coronary Atherosclerotic Heart Disease Combined with Chronic Heart Failure

Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis.

Effects of Different Statin Regiments on Lipid Profile and Serum Uric Acid in Patients with Coronary Heart Disease

Effects of different lipid-lowering treatments on coronary atherosclerotic heart disease patients with statin intolerance

Effect of rosuvastatin on clinical prognosis in patients with acute myocardial infarction complicated with atrial fibril -lation

Investigation of the efficacy of beta-blockers and reninangiotensin-aldosterone system inhibitors in chronic heart failure with preserved ejection fraction